

Jonas Busch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5790576/publications.pdf>

Version: 2024-02-01

75
papers

1,621
citations

331670

21
h-index

315739

38
g-index

80
all docs

80
docs citations

80
times ranked

2581
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients. <i>Nature Communications</i> , 2020, 11, 929.	12.8	113
2	Identification of Metastamirs as Metastasis-associated MicroRNAs in Clear Cell Renal Cell Carcinomas. <i>International Journal of Biological Sciences</i> , 2012, 8, 1363-1374.	6.4	92
3	Piwi-interacting RNAs as novel prognostic markers in clear cell renal cell carcinomas. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 61.	8.6	90
4	Residual Tumor Size and IGCCCG Risk Classification Predict Additional Vascular Procedures in Patients with Germ Cell Tumors and Residual Tumor Resection: A Multicenter Analysis of the German Testicular Cancer Study Group. <i>European Urology</i> , 2012, 61, 403-409.	1.9	82
5	Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. <i>Analytical Biochemistry</i> , 2011, 417, 233-241.	2.4	78
6	Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role. <i>Journal of Urology</i> , 2018, 199, 370-377.	0.4	71
7	Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy. <i>Clinica Chimica Acta</i> , 2013, 416, 5-10.	1.1	62
8	Cooperative Effect of miR-141-3p and miR-145-5p in the Regulation of Targets in Clear Cell Renal Cell Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0157801.	2.5	61
9	Renal cell carcinoma with venous extension: prediction of inferior vena cava wall invasion by MRI. <i>Cancer Imaging</i> , 2018, 18, 17.	2.8	56
10	Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. <i>BMC Cancer</i> , 2011, 11, 295.	2.6	54
11	Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients. <i>Clinica Chimica Acta</i> , 2016, 452, 109-119.	1.1	52
12	Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , 2012, 48, 1023-1030.	2.8	46
13	Sequence Therapy in Patients with Metastatic Renal Cell Carcinoma: Comparison of Common Targeted Treatment Options Following Failure of Receptor Tyrosine Kinase Inhibitors. <i>European Urology</i> , 2011, 60, 1163-1170.	1.9	43
14	Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes. <i>Radiology</i> , 2019, 292, 250-257.	7.3	40
15	Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages. <i>Urologia Internationalis</i> , 2021, 105, 169-180.	1.3	37
16	Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance. <i>BJU International</i> , 2014, 114, 517-521.	2.5	33
17	Male Extragenital Germ Cell Tumors of the Adult. <i>Oncology Research and Treatment</i> , 2016, 39, 140-144.	1.2	32
18	Native T1 Mapping as an In Vivo Biomarker for the Identification of Higher-Grade Renal Cell Carcinoma. <i>Investigative Radiology</i> , 2019, 54, 118-128.	6.2	31

#	ARTICLE	IF	CITATIONS
19	Long-term oncological and continence outcomes after laparoscopic radical prostatectomy: a single-centre experience. <i>BJU International</i> , 2012, 110, E985-E990.	2.5	30
20	Use of quantitative T2 mapping for the assessment of renal cell carcinomas: first results. <i>Cancer Imaging</i> , 2019, 19, 35.	2.8	25
21	Retrospective Comparison of Triple-sequence Therapies in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2013, 64, 62-70.	1.9	23
22	Efficacy of nivolumab/ipilimumab in patients with initial or late progression with nivolumab: Updated analysis of a tailored approach in advanced renal cell carcinoma (TITAN-RCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4576-4576.	1.6	23
23	Comparison of surgical technique (Open vs. Laparoscopic) on pathological and long term functional outcomes following radical prostatectomy. <i>BMC Urology</i> , 2014, 14, 18.	1.4	22
24	Oncological outcomes, quality of life outcomes and complications of partial cystectomy for selected cases of muscle-invasive bladder cancer. <i>Scientific Reports</i> , 2018, 8, 8360.	3.3	22
25	Laparoscopic and open postchemotherapy retroperitoneal lymph node dissection in patients with advanced testicular cancer – a single center analysis. <i>BMC Urology</i> , 2012, 12, 15.	1.4	21
26	Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , 2014, 50, 563-569.	2.8	20
27	Matched comparison of outcomes following open and minimally invasive radical prostatectomy for high-risk patients. <i>World Journal of Urology</i> , 2014, 32, 1411-1416.	2.2	19
28	Does the Prostate Health Index Depend on Tumor Volume? – A Study on 196 Patients after Radical Prostatectomy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 488.	4.1	19
29	Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II – Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy. <i>Urologia Internationalis</i> , 2021, 105, 181-191.	1.3	19
30	The prostate health index PHI predicts oncological outcome and biochemical recurrence after radical prostatectomy - analysis in 437 patients. <i>Oncotarget</i> , 2017, 8, 79279-79288.	1.8	19
31	miR-9-5p in Nephrectomy Specimens is a Potential Predictor of Primary Resistance to First-Line Treatment with Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2018, 10, 321.	3.7	18
32	Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma. <i>Future Oncology</i> , 2020, 16, 2307-2328.	2.4	17
33	Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors. <i>World Journal of Urology</i> , 2013, 31, 805-809.	2.2	15
34	Assessment of the extracellular volume fraction for the grading of clear cell renal cell carcinoma: first results and histopathological findings. <i>European Radiology</i> , 2019, 29, 5832-5843.	4.5	15
35	Outcome of kidney function after ischaemic and zero-ischaemic laparoscopic and open nephron-sparing surgery for renal cell cancer. <i>BMC Nephrology</i> , 2019, 20, 40.	1.8	14
36	Circulating and Tissue Expression Levels of YKL-40 in Renal Cell Cancer. <i>Journal of Urology</i> , 2016, 195, 1120-1125.	0.4	13

#	ARTICLE	IF	CITATIONS
37	Cost-effectiveness analysis of multiple imaging modalities in diagnosis and follow-up of intermediate complex cystic renal lesions. <i>BJU International</i> , 2021, 128, 575-585.	2.5	13
38	Oncologic outcomes between open and robotic-assisted radical cystectomy: a propensity score matched analysis. <i>World Journal of Urology</i> , 2014, 32, 1441-1446.	2.2	12
39	Endocytosis-Mediated Replenishment of Amino Acids Favors Cancer Cell Proliferation and Survival in Chromophobe Renal Cell Carcinoma. <i>Cancer Research</i> , 2020, 80, 5491-5501.	0.9	11
40	Risk prediction models for biochemical recurrence after radical prostatectomy using prostate-specific antigen and Gleason score. <i>Asian Journal of Andrology</i> , 2014, 16, 897.	1.6	11
41	Value of Prostate Specific Antigen Density and Percent Free Prostate Specific Antigen for Prostate Cancer Prognosis. <i>Journal of Urology</i> , 2012, 188, 2165-2170.	0.4	10
42	Matched comparison of robot-assisted, laparoscopic and open radical prostatectomy regarding pathologic and oncologic outcomes in obese patients. <i>World Journal of Urology</i> , 2015, 33, 397-402.	2.2	10
43	Significant reduction in positive surgical margin rate after laparoscopic radical prostatectomy by application of the modified surgical margin recommendations of the 2009 International Society of Urological Pathology consensus. <i>BJU International</i> , 2016, 118, 750-757.	2.5	10
44	Identification of miR-21-5p and miR-210-3p serum levels as biomarkers for patients with papillary renal cell carcinoma: a multicenter analysis. <i>Translational Andrology and Urology</i> , 2020, 9, 1314-1322.	1.4	10
45	Selective Lymph Node Dissection for Castration-Resistant Prostate Cancer. <i>Urologia Internationalis</i> , 2012, 88, 441-446.	1.3	9
46	Impact of positive surgical margins on oncological outcome following laparoscopic radical prostatectomy (LRP): long-term results. <i>World Journal of Urology</i> , 2013, 31, 395-401.	2.2	9
47	Outcome of Patients after Third and Fourth Kidney Transplantation. <i>Urologia Internationalis</i> , 2016, 97, 445-449.	1.3	9
48	Long-Term Donor Outcomes after Pure Laparoscopic versus Open Living Donor Nephrectomy: Focus on Pregnancy Rates, Hypertension and Quality of Life. <i>Urologia Internationalis</i> , 2016, 97, 450-456.	1.3	9
49	Decreased Mitochondrial DNA Content Drives OXPHOS Dysregulation in Chromophobe Renal Cell Carcinoma. <i>Cancer Research</i> , 2020, 80, 3830-3840.	0.9	9
50	Efficacy of fourth-line targeted therapy in patients with metastatic renal cell carcinoma: a retrospective analysis. <i>World Journal of Urology</i> , 2016, 34, 1147-1154.	2.2	7
51	Serum Vitamin D is Not Helpful for Predicting Prostate Cancer Aggressiveness Compared with the Prostate Health Index. <i>Journal of Urology</i> , 2016, 196, 709-714.	0.4	7
52	Fate of Finally Transplanted Deceased Donor Kidneys Initially Rejected at Other Kidney Transplantation Centers. <i>Urologia Internationalis</i> , 2014, 93, 474-481.	1.3	5
53	Limited utility of qPCR-based detection of tumor-specific circulating mRNAs in whole blood from clear cell renal cell carcinoma patients. <i>BMC Urology</i> , 2020, 20, 7.	1.4	5
54	Complications, functional and quality of life outcomes following primary and secondary implantation of penile prosthesis at a tertiary referral center. <i>International Journal of Impotence Research</i> , 2018, 30, 49-53.	1.8	5

#	ARTICLE	IF	CITATIONS
55	Retrospective Analysis of Fifth-Line Targeted Therapy Efficacy in Patients with Metastatic Renal Cell Carcinoma. <i>Urologia Internationalis</i> , 2017, 98, 184-190.	1.3	4
56	Prevalence of Late-Onset Hypogonadism in Men with Localized and Metastatic Renal Cell Carcinoma. <i>Urologia Internationalis</i> , 2017, 98, 191-197.	1.3	4
57	Perioperative Changes and Progress in Photoselective Vaporization of the Prostate with GreenLight XPS 180 W System: A Single Center Experience. <i>Urologia Internationalis</i> , 2018, 100, 463-469.	1.3	4
58	Additive Value of Transrectal Systematic Ventral Biopsies in Combination with Magnet Resonance Imaging/Ultrasound Fusion-Guided Biopsy in Patients with 3 or More Negative Prostate Biopsies. <i>Urologia Internationalis</i> , 2020, 104, 205-213.	1.3	4
59	Can magnetic resonance imaging replace conventional computerized tomography for follow-up of patients with testicular cancer? A systematic review. <i>World Journal of Urology</i> , 2022, 40, 2843-2852.	2.2	4
60	Staging lymphadenectomy in patients with localized high risk prostate cancer: comparison of the laparoendoscopic single site (LESS) technique with conventional multiport laparoscopy. <i>BMC Urology</i> , 2014, 14, 92.	1.4	2
61	The Effect of Evolving Strategies in the Surgical Management of Organ-Confined Prostate Cancer: Comparison of Data from 2005 to 2014 in a Multicenter Setting. <i>Advances in Therapy</i> , 2017, 34, 576-585.	2.9	2
62	Perioperative and oncologic outcome in patients treated for renal cell carcinoma with an extended inferior vena cava tumour thrombus level II-IV. <i>Aktuelle Urologie</i> , 2019, , .	0.3	2
63	Lymphatic micrometastases predict biochemical recurrence in patients undergoing radical prostatectomy and pelvic lymph node dissection for prostate cancer. <i>Aktuelle Urologie</i> , 2019, 50, 612-618.	0.3	2
64	The value of digital rectal examination in clinical practice. <i>AME Medical Journal</i> , 0, 3, 45-45.	0.4	1
65	Analysis of quality of life and late biochemical predictors for localized cancer recurrence following radical prostatectomy. <i>World Journal of Urology</i> , 2020, 38, 1501-1507.	2.2	1
66	Urolithiasis in Renal Allografts: Complications and Outcomes. <i>Experimental and Clinical Transplantation</i> , 2017, 15, 164-170.	0.5	1
67	First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment. <i>World Journal of Urology</i> , 2022, , 1.	2.2	1
68	1013 SINGLE PORT LAPAROSCOPIC VARICOCELECTOMY: INITIAL EXPERIENCE AND COMPARISON WITH THE CONVENTIONAL MULTIPORT LAPAROSCOPIC TECHNIQUE. <i>Journal of Urology</i> , 2012, 187, .	0.4	0
69	472 EPIGENETICALLY REPRESSED MIRNAS AS PREDICTORS OF TUMOR RECURRENCE IN CLEAR CELL RENAL CELL CARCINOMA PATIENTS FOLLOWING RADICAL NEPHRECTOMY. <i>Journal of Urology</i> , 2013, 189, .	0.4	0
70	MP85-18 CIRCULATING FREE GENOMIC AND MITOCHONDRIAL DNA FRAGMENTS AND THEIR DIAGNOSTIC AND PROGNOSTIC POTENTIAL IN CLEAR CELL RENAL CELL CARCINOMA PATIENTS. <i>Journal of Urology</i> , 2016, 195, .	0.4	0
71	MP59-19 OUTCOME OF KIDNEY FUNCTION AFTER ISCHAEMIC AND ZERO-ISCHAEMIC LAPAROSCOPIC AND OPEN NEPHRON-SPARING SURGERY FOR RCC. <i>Journal of Urology</i> , 2017, 197, .	0.4	0
72	Tumor shrinkage during VEGF inhibitor therapy as an independent predictor of PFS and OS in renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 423-423.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Management of growing teratoma syndrome (GTS): Results of the German Testicular Cancer Study Group.. Journal of Clinical Oncology, 2018, 36, 566-566.	1.6	0
74	Early Continence and Extravasation After Open Retropubic Radical Prostatectomy “ Interrupted vs Continuous Suturing for Vesicourethral Anastomosis. Therapeutics and Clinical Risk Management, 2020, Volume 16, 1289-1296.	2.0	0
75	Novel predictive biomarkers of response to immune checkpoint blockade with nivolumab ± ipilimumab in the TITAN-RCC phase 2 trial.. Journal of Clinical Oncology, 2022, 40, 367-367.	1.6	0